Title |
A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial
|
---|---|
Published in |
Trials, October 2020
|
DOI | 10.1186/s13063-020-04746-9 |
Pubmed ID | |
Authors |
Shin Takayama, Takao Namiki, Takashi Ito, Ryutaro Arita, Hajime Nakae, Seiichi Kobayashi, Tetsuhiro Yoshino, Tomoaki Ishigami, Koichiro Tanaka, Mosaburo Kainuma, Kotaro Nochioka, Airi Takagi, Masaru Mimura, Takuhiro Yamaguchi, Tadashi Ishii |
X Demographics
The data shown below were collected from the profiles of 23 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 4 | 17% |
United States | 2 | 9% |
United Kingdom | 1 | 4% |
Unknown | 16 | 70% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 21 | 91% |
Practitioners (doctors, other healthcare professionals) | 1 | 4% |
Science communicators (journalists, bloggers, editors) | 1 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 186 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 186 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 21 | 11% |
Student > Master | 19 | 10% |
Other | 17 | 9% |
Researcher | 17 | 9% |
Lecturer | 13 | 7% |
Other | 37 | 20% |
Unknown | 62 | 33% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 45 | 24% |
Nursing and Health Professions | 22 | 12% |
Pharmacology, Toxicology and Pharmaceutical Science | 9 | 5% |
Psychology | 8 | 4% |
Biochemistry, Genetics and Molecular Biology | 6 | 3% |
Other | 26 | 14% |
Unknown | 70 | 38% |